Bobadilla NA

Language: Spanish
References: 55
Page: 470-480
PDF size: 176.35 Kb.

Text Extraction

No abstract.

REFERENCES

1. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 2000; 20: 4-19.

2. Weight SC, Bell PR, Nicholson ML. Renal ischaemia—reperfusion injury. Br J Surg 1996; 83: 162-70.

3. Kelly KJ. Acute renal failure: much more than a kidney disease. Semin Nephrol 2006; 26: 105-13.

4. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-91.

5. Druml W. Long term prognosis of patients with acute renal failure: is intensive care worth it? Intensive Care Med 2005; 31: 1145-7.

6. Tait SA, Tait JF. The correspondence of S.A.S. Simpson and J.F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone). Steroids 1998; 63: 440-53.

7. Kim GH, Masilamani S, Turner R, et al. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci 1998; 95: 14552-7.

8. Masilamani S, Kim GH, Mitchell C, et al. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest 1999; 104: R19-R23.

9. Seok JH, Hong JH, Jeon JR, et al. Aldosterone directly induces Na, K-ATPase alpha 1-subunit mRNA in the renal cortex of rat. Biochem Mol Biol Int 1999; 47: 251-4.

10. Ngarmukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 2001; 281: E1122-E1127.

11. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J 2007; 54: 359-70.

12. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.

13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.

14. Chrysostomou A, Pedagogos E, MacGregor L, et al. Double- Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker. Clin J Am Soc Nephrol 2006; 1: 256-62.

15. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-6.

16. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003; 14: 2395-401.

17. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10: 31-7.

18. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-8.

19. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-8.

20. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-800.

21. Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-7.

22. Trachtman H, Weiser AC, Valderrama E, et al. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 2004; 172: 1590-4.

23. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-72.

24. Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006; 147: 5363-73.

25. Rocha R, Stier CT, Jr., Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-8.

26. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9.

27. Juknevicius I, Segal Y, Kren S, et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286: F1059-F1062.

28. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-9.

29. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.

30. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990; 1: 162-79.

31. European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant 2000; 15(Suppl. 7): 1-85.

32. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-46.

33. Li C, Yang CW, Kim WY, et al. Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine. Am J Physiol Renal Physiol 2003; 284: F389-F398.

34. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int Suppl 1995; 52: S63-S69.

35. Perico N, Benigni A, Bosco E, et al. Acute cyclosporine A nephrotoxicity in rats: which role for renin- angiotensin system and glomerular prostaglandins? Clin Nephrol 1986; 25(Suppl. 1): S83-S88.

36. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 1990; 49: 445-52.

37. Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52.

38. Perez-Rojas JM, Derive S, Blanco JA, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005; 289: F1020-F1030.

39. Perez-Rojas J, Blanco JA, Cruz C, et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2006; 292: F131-F139.

40. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-63.

41. Gros R, Ding Q, Armstrong S, et al. Rapid Effects of Aldosterone on Clonal Human Vascular Smooth Muscle Cells. Am J Physiol Cell Physiol 2006; 292: C788-C794.

42. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984; 246: H608-H614.

43. Robert V, Heymes C, Silvestre JS, et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone- salt-induced fibrosis. Hypertension 1999; 33: 981-6.

44. Mejia-Vilet JM, Ramirez V, Cruz C, et al. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007; 293: F78-F86.

45. Schrier RW, Wang W, Poole B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114: 5-14.

46. Goligorsky MS, Brodsky SV, Noiri E. NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology. Semin Nephrol 2004; 24: 316-23.

47. Yamasowa H, Shimizu S, Inoue T, et al. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J Pharmacol Exp Ther 2005; 312: 153-9.

48. Versteilen AM, Korstjens IJ, Musters RJ, et al. Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia- reperfusion of the rat kidney. Am J Physiol Renal Physiol 2006; 291: F606-F611.

49. Nagata D, Takahashi M, Sawai K, et al. Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity. Hypertension 2006; 48: 165-71.

50. Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-12.

51. Rude MK, Duhaney TA, Kuster GM, et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 2005; 46: 555-61.

52. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004; 66: 500-6.

53. Joo JD, Kim M, D’Agati VD, et al. Ischemic preconditioning provides both acute and delayed protection against renal ischemia and reperfusion injury in mice. J Am Soc Nephrol 2006; 17: 3115-23.

54. Daemen MA, van’t Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104: 541-9.

55. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-97.